Cardiac hypertrophy (CH) is an augmentation of either the right ventricular or the left ventricular mass in order to compensate for the increase of work load on the heart. Metabolic abnormalities lead to histological changes of cardiac myocytes and turn into CH. The molecular mechanisms that lead to initiate CH have been of widespread concern, hence the development of the new field of research, metabolomics: one ‘omics’ approach that can reveal comprehensive information of the paradigm shift of metabolic pathways network in contrast to individual enzymatic reaction-based metabolites, have attempted and until now only 19 studies have been conducted using experimental animal and human specimens. Nuclear magnetic resonance spectroscopy and mass spectrometry-based metabolomics studies have found that CH is a metabolic disease and is mainly linked to the harmonic imbalance of glycolysis, citric acid cycle, amino acids and lipid metabolism. The current review will summarise the main outcomes of the above mentioned 19 studies that have expanded our understanding of the molecular mechanisms that may lead to CH and eventually to heart failure.

中文翻译：

---

代谢组学在识别心脏肥大中的作用：过去 20 年发展概述和未来展望

心脏肥大 (CH) 是右心室或左心室质量的增加，以补偿心脏工作负荷的增加。代谢异常导致心肌细胞的组织学变化并转化为CH。导致启动 CH 的分子机制受到广泛关注，因此新研究领域的发展，代谢组学：一种“组学”方法，可以揭示代谢途径网络范式转变的综合信息，而不是个体酶促反应基于代谢物，已经尝试过，到目前为止，仅使用实验动物和人体标本进行了 19 项研究。基于核磁共振波谱和质谱的代谢组学研究发现，CH是一种代谢性疾病，主要与糖酵解、柠檬酸循环、氨基酸和脂质代谢的谐波失衡有关。本综述将总结上述 19 项研究的主要成果，这些研究扩大了我们对可能导致 CH 并最终导致心力衰竭的分子机制的理解。